Blood Cell Palmitoleate-Palmitate Ratio Is an Independent Prognostic Factor for Amyotrophic Lateral Sclerosis

PLoS One. 2015 Jul 6;10(7):e0131512. doi: 10.1371/journal.pone.0131512. eCollection 2015.

Abstract

Growing evidence supports a link between fatty acid metabolism and amyotrophic lateral sclerosis (ALS). Here we determined the fatty acid composition of blood lipids to identify markers of disease progression and survival. We enrolled 117 patients from two clinical centers and 48 of these were age and gender matched with healthy volunteers. We extracted total lipids from serum and blood cells, and separated fatty acid methyl esters by gas chromatography. We measured circulating biochemical parameters indicative of the metabolic status. Association between fatty acid composition and clinical readouts was studied, including ALS functional rating scale-revised (ALSFRS-R), survival, disease duration, site of onset and body mass index. Palmitoleate (16:1) and oleate (18:1) levels, and stearoyl-CoA desaturase indices (16:1/16:0 and 18:1/18:0) significantly increased in blood cells from ALS patients compared to healthy controls. Palmitoleate levels and 16:1/16:0 ratio in blood cells, but not body mass index or leptin concentrations, negatively correlated with ALSFRS-R decline over a six-month period (p<0.05). Multivariate Cox analysis, with age, body mass index, site of onset and ALSFRS-R as covariables, showed that blood cell 16:1/16:0 ratio was an independent prognostic factor for survival (hazard ratio=0.1 per unit of ratio, 95% confidence interval=0.01-0.57, p=0.009). In patients with high 16:1/16:0 ratio, survival at blood collection was extended by 10 months, as compared to patients with low ratio. The 16:1/16:0 index is an easy-to-handle parameter that predicts survival of ALS patients independently of body mass index. It therefore deserves further validation in larger cohorts for being used to assess disease outcome and effects of disease-modifying drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Amyotrophic Lateral Sclerosis / blood*
  • Amyotrophic Lateral Sclerosis / mortality*
  • Body Mass Index
  • Case-Control Studies
  • Disease Progression
  • Fatty Acids, Monounsaturated / blood*
  • Female
  • Humans
  • Leptin / blood
  • Male
  • Middle Aged
  • Palmitic Acid / blood*
  • Prognosis
  • Severity of Illness Index
  • Survival Rate

Substances

  • Fatty Acids, Monounsaturated
  • Leptin
  • palmitoleic acid
  • Palmitic Acid

Grants and funding

This work was supported by funds from Thierry Latran Foundation, European Community's Health Seventh Framework Programme under grant agreement No. 259867 (Euro-MOTOR), "Association pour la Recherche sur la Sclérose Latérale Amyotrophique et autres Maladies du Motoneurone" (ARSLA), "André combat la SLA" and “Association pour la Recherche et le Développement de Moyens de Lutte contre les Maladies Neurodégénératives” (AREMANE). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.